Oragenics shareholders approve 84x increase in authorized shares to 350M and expansion of equity plan

On December 14, 2023, the Company filed Articles of Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Florida to increase the number of authorized shares from 4,166,666 shares of Common Stock to 350,000,000 shares of Common Stock

PROPOSAL VII: Ratification of the selection of Cherry Bekaert LLP as the Company's independent auditors for the year ending December 31, 2023. The votes were as follows: FOR 756,720 AGAINST 146,619 ABSTAIN 3,265

The Annual Meeting was held on December 14, 2023. (b) At the Annual Meeting the following proposals were voted on by our shareholders: PROPOSAL I: Election of Directors. Mr. Charles Pope, Dr. Frederick Telling, Mr. Robert Koski, Dr. Alan Dunton, Ms. Kim Murphy, Mr. John Gandolfo and Mr. Bruce Cassidy were each re-elected as Directors, to serve until our next annual meeting of shareholders or until their respective successors are elected and qualified or until their earlier resignation, removal from office or death.

PROPOSAL V: To approve the issuance of the Common Stock upon conversion of the Company's Series F Convertible Preferred Stock. The votes were as follows: FOR 834,513 AGAINST 60,666 ABSTAIN 11,425

PROPOSAL VI : To approve an amendment to the Company's 2021 Equity Incentive Plan to increase the number of common shares available for issuance under the 2021 Equity Incentive Plan from 166,667 shares of Common Stock to 1,166,667 shares of Common Stock.

PROPOSAL III: To approve the adoption of an amendment to our Amended and Restated Articles of Incorporation which will increase the number of authorized shares of our Common Stock from 4,166,666 shares of Common Stock to 350,000,000 shares of Common Stock.

PROPOSAL II: To conduct a non-binding advisory vote on executive compensation. The votes were as follows: FOR 794,152 AGAINST 105,633 ABSTAIN 6,819